Valerie joined OrbiMed in 2022 and is a Venture Partner. Prior to joining OrbiMed, Valerie was the President and Chief Scientific Officer of Silverback Therapeutics, a biopharmaceutical company advancing a pipeline of tissue-targeted therapies across multiple therapeutic areas. Previously, Valerie served as Vice President of Research at Juno Therapeutics, where she was responsible for the discovery and development of novel immunotherapies for cancer. Prior to Juno, she held research leadership positions at Novo Nordisk and Trubion, where she was responsible for the advancement of therapeutics for oncology and inflammatory conditions. Valerie received her bachelor’s degree in Biology and Chemistry from Wake Forest University and her Ph.D. in Immunobiology from Yale University.